WEBULL
News
QUCY
0.7374
-2.77%
-0.0210
Mainz Biomed changes ticker symbol to "QUCY"
Seeking Alpha · 2d ago
Mainz Biomed Rebrands As Quantum Cyber; Ticker Shifts To QUCY On Nasdaq
Benzinga · 2d ago
Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY
Barchart · 2d ago
Mainz Biomed Rebrands as Quantum Cyber, Reshapes Leadership
TipRanks · 4d ago
Mainz Biomed appoints Liscouski as Chairman, to change name to Quantum Cyber
TipRanks · 4d ago
Mainz Biomed Appoints Robert Liscouski As Chairman Of Its Board Of Directors; Co Plans To Change Its Name To Quantum Cyber And Nasdaq Ticker Symbol To QUCY, Effective March 12
Benzinga · 4d ago
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
Barchart · 4d ago
Weekly Report: what happened at MYNZ last week (0302-0306)?
Weekly Report · 6d ago
Mainz Biomed cut to Hold at Maxim on shift in capital structure
TipRanks · 03/06 13:53
Mainz Biomed downgraded to Hold from Buy at Maxim
TipRanks · 03/06 13:03
Weekly Report: what happened at MYNZ last week (0223-0227)?
Weekly Report · 03/02 09:13
Mainz Biomed To Present Poster Titled BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS At Digestive Disease Week In Chicago
Benzinga · 02/24 12:44
Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples
Barchart · 02/24 06:30
Weekly Report: what happened at MYNZ last week (0216-0220)?
Weekly Report · 02/23 09:13
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 02/17 21:06
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 02/17 17:05
Mainz Biomed Secures Strategic Investment and Restructures Operations
TipRanks · 02/17 13:00
Mainz Biomed to focus on pancreatic cancer detection business in the U.S.
TipRanks · 02/17 12:40
Mainz Biomed secures $6 million private placement, shifts focus to U.S. pancreatic cancer program
Seeking Alpha · 02/17 12:39
Mainz Biomed Raises $6M Private Placement To Fund Operations And Shift Focus To Pancreatic Cancer Screening
Benzinga · 02/17 12:35
More
Webull provides a variety of real-time QUCY stock news. You can receive the latest news about Mainz Biomed NV through multiple platforms. This information may help you make smarter investment decisions.
About QUCY
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.